NGNE
Neurogene Inc
31.30$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +148.4% | -12.2% | -7.9% | -8.7% | +104.6% | -6.1% | -5.7% | -3.2% | +0.5% | -9.0% | -7.1% | |
| – | +150.8% | -13.1% | -8.6% | -9.7% | +119.9% | -6.2% | -5.9% | -3.0% | +0.4% | -9.1% | -7.2% | |
| – | +487.5% | +1.3% | -26.0% | -40.0% | +105.0% | -48.2% | -16.9% | +20.7% | +46.3% | +19.6% | -9.4% | |
| – | +151.1% | -14.0% | -9.2% | -9.7% | +124.8% | -6.3% | -6.2% | -3.3% | +1.4% | -9.6% | -7.3% | |
| – | – | -1.8% | +9.8% | +3.9% | -3.6% | -8.0% | +119.6% | -34.3% | -46.5% | – | – | |
| – | +154.7% | -32.8% | +1.0% | +7.6% | -5.1% | -7.3% | +2.4% | -7.4% | +9.0% | +4.4% | +7.4% | |
| – | +340.8% | -48.6% | +10.6% | +20.9% | -4.1% | -7.0% | +9.6% | -4.7% | +11.6% | +15.0% | +14.0% | |
| – | +23.4% | -5.9% | +3.8% | +30.6% | -18.5% | +39.4% | +2.4% | -12.6% | -18.1% | -0.6% | -0.7% | |
| – | +21.6% | -41.4% | +13.3% | -2.3% | -20.7% | +129.3% | -32.7% | -25.0% | +26.5% | +139.9% | -29.7% | |
| – | +147.3% | -8.2% | -9.2% | -11.4% | +125.9% | -6.0% | -6.4% | -2.8% | -0.2% | -10.2% | -8.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +15.5% | +31.8% | +0.2% | +0.1% | -12.4% | +41.3% | +0.3% | +0.5% | -26.8% | +44.0% | +1.1% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.